Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial

CONCLUSIONS: FINE-ONE will evaluate the efficacy and safety of finerenone in T1D and CKD. Finerenone could become the first registered treatment for CKD associated with T1D in almost 30 years.TRIAL REGISTRATION: ClinicalTrials.gov NCT05901831.PMID:37805000 | DOI:10.1016/j.diabres.2023.110908

Source: Clin Med Res - October 7, 2023 Category: Research Authors: Hiddo J L Heerspink Andreas L Birkenfeld David Z I Cherney Helen M Colhoun Linong Ji Chantal Mathieu Per-Henrik Groop Richard E Pratley Sylvia E Rosas Peter Rossing Jay S Skyler Katherine R Tuttle Robert Lawatscheck Charlie Scott Robert Edfors Markus F Sc Source Type: research